SCHEMBL14246722

SCHEMBL14246722

COc1cc(OC)c2c(C)c(Cc3cccc(Cl)c3)c(=O)[nH]c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
TOP2A P11388 1/20 0.41
CCNB2 O95067 1/20 0.40
CCNE2 O96020 1/20 0.40
CDK1 P06493 1/20 0.40
CDK4 P11802 1/20 0.40
CCNB1 P14635 1/20 0.40
CCND1 P24385 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
MAOB P27338 1/20 0.40
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15931625 0.89 ABCG2 (0.44) PDE10AABCG2PDE3BPDE3AMAPT
SCHEMBL14317881 0.88 MAPT (0.47) PDE10AABCG2PDE3BPDE3ATOP2A
SCHEMBL6590133 0.88 ABCG2 (0.50) PDE10AABCG2TP53MEN1ALDH1A1
SCHEMBL14317883 0.86 GRIN1 (0.43) PDE10AABCG2PDE3BPDE3ATOP2A
SCHEMBL14317180 0.86 ABCG2 (0.41) PDE10AABCG2PDE3BPDE3AMAPT
SCHEMBL15931676 0.85 ABCG2 (0.40) PDE10AABCG2PDE3BPDE3ACCNB2
SCHEMBL15931626 0.83 ABCG2 (0.44) PDE10AABCG2PDE3BPDE3AMEN1
SCHEMBL14246819 0.81 ABCG2 (0.43) PDE10AABCG2PDE3BPDE3AMEN1
SCHEMBL14246753 0.81 LMNA (0.46) ABCG2MAPTMEN1LMNAKMT2A
SCHEMBL6583774 0.80 ABCG2 (0.49) PDE10AABCG2PDE3BPDE3ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 PDE10A 479/4885ABCG2 2808/4885PDE3B 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.